Nova Eye Financials
| EYE Stock | 0.15 0.01 7.14% |
Operating Margin (0.26) | Profit Margin (0.38) | EPS Estimate Current Year (0.04) | Return On Equity (0.39) |
Nova | Select Account or Indicator |
Understanding current and past Nova Eye Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Nova Eye's financial statements are interrelated, with each one affecting the others. For example, an increase in Nova Eye's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Nova Eye's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nova Eye Medical. Check Nova Eye's Beneish M Score to see the likelihood of Nova Eye's management manipulating its earnings.
Nova Eye Stock Summary
Nova Eye competes with FSA, Tamawood, Rea, CSL, and Macquarie. Nova Eye is entity of Australia. It is traded as Stock on AU exchange.| Foreign Associate | USA |
Specialization | Health Care, Health Care Equipment & Services |
| Instrument | Australia Stock View All |
| Exchange | Australian Securities Exchange |
| ISIN | AU0000094252 |
| Business Address | 107 Rundle Street, |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.nova-eye.com |
| Phone | 61 8 8362 0193 |
You should never invest in Nova Eye without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Nova Stock, because this is throwing your money away. Analyzing the key information contained in Nova Eye's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Nova Eye Key Financial Ratios
Nova Eye's financial ratios allow both analysts and investors to convert raw data from Nova Eye's financial statements into concise, actionable information that can be used to evaluate the performance of Nova Eye over time and compare it to other companies across industries.| Revenue | 23.32 M | ||||
| Gross Profit | 14.39 M | ||||
| EBITDA | (5.98 M) | ||||
| Net Income | (8.79 M) | ||||
| Cash And Equivalents | 7.42 M |
Nova Eye Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 116.7M | 42.0M | 36.6M | 30.4M | 29.9M | 40.5M | |
| Other Current Liab | 472K | 746K | 912K | 1.3M | 1.6M | 2.7M | |
| Net Debt | (92.3M) | (14.1M) | (6.1M) | (5.9M) | (2.8M) | (2.7M) | |
| Retained Earnings | 24.6M | 892K | (6.6M) | (21.9M) | (30.7M) | (29.2M) | |
| Accounts Payable | 3.8M | 2.0M | 2.4M | 4.3M | 3.6M | 2.8M | |
| Cash | 95.6M | 17.8M | 8M | 7.4M | 6.2M | 6.6M | |
| Net Receivables | 3.8M | 1.9M | 2.0M | 1.9M | 4.1M | 6.4M | |
| Inventory | 2.9M | 2.9M | 3.5M | 3.8M | 4.3M | 4.1M | |
| Total Liab | 16.2M | 6.7M | 6.2M | 7.2M | 8.6M | 11.4M | |
| Total Current Assets | 102.9M | 26.3M | 15.6M | 14.6M | 14.7M | 22.8M | |
| Short Term Debt | 1.9M | 1.9M | 544K | 639K | 480K | 456K | |
| Other Current Assets | 494K | 3.7M | 2.0M | 1.4M | 234K | 222.3K | |
| Intangible Assets | 10.9M | 12.1M | 18.0M | 13.3M | 7.0M | 6.8M | |
| Other Assets | 7.6M | 8.7M | 10.9M | 4.9M | 4.4M | 4.2M | |
| Long Term Debt Total | 1.4M | 1.8M | 1.4M | 892K | 802.8K | 1.3M | |
| Other Liab | 1.7M | 365K | 212K | 966K | 869.4K | 1.0M | |
| Net Tangible Assets | 97.2M | 31.9M | 23.2M | 14.7M | 13.3M | 12.6M | |
| Net Invested Capital | 102.1M | 36.8M | 30.4M | 23.2M | 21.3M | 20.3M | |
| Short Long Term Debt | 9.0M | 14.9M | 1.6M | 1.4M | 1.3M | 1.2M |
Nova Eye Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 63K | 68K | 64K | 54K | 70K | 66.5K | |
| Total Revenue | 12.8M | 13.4M | 13.4M | 17.0M | 23.3M | 30.6M | |
| Gross Profit | (1.6M) | 1.8M | (765K) | 842K | 20.2M | 15.5M | |
| Operating Income | (7.2M) | (5.0M) | (9.9M) | (11.8M) | (3.8M) | (3.6M) | |
| Ebit | (7.2M) | (5.2M) | (9.7M) | (11.8M) | (9.0M) | (8.5M) | |
| Ebitda | (5.7M) | (3.7M) | (7.9M) | (9.5M) | (6.0M) | (5.7M) | |
| Income Before Tax | (7.2M) | (5.3M) | (7.8M) | (17.0M) | (8.8M) | (8.4M) | |
| Income Tax Expense | 3.1M | (894K) | (321K) | (1.7M) | (5.2M) | (4.9M) | |
| Net Income | (7.0M) | (4.4M) | (7.5M) | (15.3M) | (8.8M) | (8.4M) | |
| Research Development | 2.0M | 107K | 162K | 617K | 567K | 1.1M | |
| Cost Of Revenue | 14.4M | 11.6M | 14.1M | 16.2M | 3.1M | 3.0M | |
| Tax Provision | (1.3M) | 3.1M | (894K) | (750K) | (1.7M) | 0.0 | |
| Interest Income | 203K | 550K | 34K | 84K | 124K | 179.0K | |
| Net Interest Income | (58K) | 171K | (30K) | 49K | 54K | 56.7K |
Nova Eye Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation | 1.4M | 1.5M | 1.8M | 2.3M | 3.0M | 3.1M | |
| Other Non Cash Items | (3.9M) | (8.7M) | 521K | 10.4M | (87K) | (82.7K) | |
| Capital Expenditures | 1.7M | 2.2M | 5.6M | 800K | 449K | 426.6K | |
| End Period Cash Flow | 95.6M | 17.8M | 8M | 7.4M | 6.2M | 6.7M | |
| Change In Cash | 80.3M | (77.8M) | (9.8M) | (581K) | (1.3M) | (1.2M) | |
| Free Cash Flow | 3.8M | (15.4M) | (10.3M) | (7.5M) | (8.3M) | (7.9M) | |
| Net Income | (10.3M) | (4.4M) | (7.5M) | (15.3M) | (8.8M) | (8.4M) | |
| Change To Inventory | 3.8M | 33K | (639K) | (266K) | (477K) | (500.9K) | |
| Net Borrowings | (13.3M) | (582K) | (402K) | (653K) | (587.7K) | (617.1K) | |
| Change To Netincome | (50.8M) | (665K) | (1.4M) | 6.0M | 5.4M | 5.7M |
Nova Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nova Eye's current stock value. Our valuation model uses many indicators to compare Nova Eye value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nova Eye competition to find correlations between indicators driving Nova Eye's intrinsic value. More Info.Nova Eye Medical is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nova Eye's earnings, one of the primary drivers of an investment's value.Nova Eye Medical Systematic Risk
Nova Eye's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nova Eye volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Nova Eye Medical correlated with the market. If Beta is less than 0 Nova Eye generally moves in the opposite direction as compared to the market. If Nova Eye Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nova Eye Medical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nova Eye is generally in the same direction as the market. If Beta > 1 Nova Eye moves generally in the same direction as, but more than the movement of the benchmark.
Nova Eye Medical Total Assets Over Time
Nova Eye Thematic Clasifications
Nova Eye Medical is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
| Drugs | View |
Nova Eye November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Nova Eye help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Nova Eye Medical. We use our internally-developed statistical techniques to arrive at the intrinsic value of Nova Eye Medical based on widely used predictive technical indicators. In general, we focus on analyzing Nova Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Nova Eye's daily price indicators and compare them against related drivers.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 20.54 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 6.67 |
Additional Tools for Nova Stock Analysis
When running Nova Eye's price analysis, check to measure Nova Eye's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nova Eye is operating at the current time. Most of Nova Eye's value examination focuses on studying past and present price action to predict the probability of Nova Eye's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nova Eye's price. Additionally, you may evaluate how the addition of Nova Eye to your portfolios can decrease your overall portfolio volatility.